In situ expression of cell growth factors in human renal chronic graft rejection.
Vuillemin
T
T
Service de Néphrologie-Urologie, Kremlin Bicêtre, Paris, France.
Legendre
C
C
Meduri
G
G
Larue
J R
JR
Goupy
C
C
Kriaa
F
F
Hiesse
C
C
Benoit
G
G
Senik
A
A
Kreis
H
H
Charpentier
B
B
D000077214:Becaplermin; D015415:Biomarkers; D002908:Chronic Disease; D004815:Epidermal Growth Factor / Q000096:biosynthesis; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology*; D006133:Growth Substances / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology*; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000096:biosynthesis; D013997:Time Factors; D014158:Transcription, Genetic; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D015415:Biomarkers; D006133:Growth Substances; D007375:Interleukin-1; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; C075278:platelet-derived growth factor A; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin; D004815:Epidermal Growth Factor